ECHNO-ICHNO 2023 - 10th European Congress on Head & Neck Oncology
Mar 08 - Mar 11, 2023 | LisbonPortugal
LARVOL is not affiliated with 10th European Congress on Head & Neck Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 13 abstracts linked to Trials
Predictive value of body composition assessment in R/M SCCHN treated with immunotherapy (NCT04721184)
Exercise prehabilitation in head & neck cancer patients: Preliminary results of the FIT4TREAT trial
Elective neck irradiation guided by sentinel node biopsy in larynx & pharynx cancer: the PRIMO trial
A randomized trial of reduced elective neck radiation dose in head & neck cancer: acute toxicity
InGReS: Intra-treatment Image-Guided Adaptive Radiotherapy Dose-escalation - a Phase 1 study
Diagnostic test accuracy of sentinel lymph node biopsy in larynx & pharynx cancers: a meta-analysis
Net treatment benefit of avasopasem manganese for severe oral mucositis from the ROMAN trial
Nivolumab in patients with head and neck cancer. Results of Polish multicenter observational study.
Real-world data on nivolumab for recurrent or metastatic squamous-cell carcinoma of head and neck
Real-world R/M HNSCC patients’ characterization during 1st line treatment in Portugal – TRACE study
Nivolumab for Head and Neck Squamous Cell Carcinoma - Retrospective Multicenter Real-World Data
Neoadjuvant Leukocyte Interleukin Injection (LI) extends locally advanced SCCHN overall survival
Durable response after neoadjuvant immunotherapy in resectable CSCC: The MATISSE trial NCT04620200